6 August 2020 in The FASEB Journal
Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs.
3 May 2024 in Chemistry – A European Journal
Cancer is one of the deadliest diseases worldwide. Chemotherapy remains one of the most dominant forms for anticancer treatment. Despite their clinical success, the used chemotherapeutic agents are associated with severe side effect and pharmacological limitations. To overcome these drawbacks there is a need for the development of new types of chemotherapeutic agents. Herein, the chemical synthesis and biological evaluation of dinuclear rhenium(I) complexes as potential chemotherapeutic drug candidates are proposed. The metal complexes were found to be internalized by an energy dependent endocytosis pathway, primary accumulating in the mitochondria. The rhenium(I) complexes demonstrated to induce cell death against a variety of cancer cells in the micromolar range through apoptosis. The lead compound showed to eradicate a pancreatic carcinoma multicellular tumor spheroid at micromolar concentrations.
14 December 2024 in JBIC Journal of Biological Inorganic Chemistry
Primary human neutrophils are the most abundant human white blood cells and are central for innate immunity. They act as early responders at inflammation sites, guided by chemotactic gradients to find infection or inflammation sites. Neutrophils can undergo both apoptosis as well as NETosis. NETosis is a form of neutrophil cell death that releases chromatin-based extracellular traps (NETs) to capture and neutralize pathogens. Understanding or controlling the balance between these cell-death mechanisms is crucial. In this study, the chemical synthesis and biologic assessment of a ruthenium complex as a light-activated photosensitizer that creates reactive oxygen species (ROS) in primary human neutrophils is reported. The ruthenium complex remains non-toxic in the dark. However, upon exposure to blue light at 450 nm, it exhibits potent cytotoxic effects in both cancerous and non-cancerous cell lines. Interestingly, the metal complex shifts the cell-death mechanism of primary human neutrophils from NETosis to apoptosis. Cells irradiated directly by the light source immediately undergo apoptosis, whereas those further away from the light source perform NETosis at a slower rate. This indicates that high ROS levels trigger apoptosis and lower ROS levels NETosis. The ability to control the type of cell death undergone in primary human neutrophils could have implications in managing acute and chronic infectious diseases. Graphical
10 March 2026 in Inorganic Chemistry Frontiers
A new generation of backbone-functionalized NHC–gold( i ) complexes reveals ferroptosis through comprehensive mechanistic and biological investigation.
19 February 2019 in Bionatura
The fatty-acid synthase (FAS) is the key enzyme that executes de novo fatty acid synthesis and is overexpressed in some human cancer tissues. C75 is a synthetic FAS inhibitor, which produces the death of cancer cells. In this work, we synthesized three derivatives of C75, two homologs with 1 and 2 carbons more in the beta position of the lactone and the other one with a change in the elongation of the aliphatic chain in gamma position from 8 to 15 carbons. The results from FAS inhibition and cytotoxic properties suggest that the performed changes in the derivatives decrease their activity.
9 September 2026 in Angewandte Chemie
ZUSAMMENFASSUNG: Die Ultraschalltechnologie hat einen grundlegenden Paradigmenwechsel durchlaufen und sich von einem herkömmlichen Diagnosegerät zu einer hochentwickelten Plattform für die nichtinvasive, ortsspezifische Krebstherapie weiterentwickelt. Durch die Nutzung des inversen piezoelektrischen Effekts erzeugt Ultraschall mechanische Wellen, die in flüssigen Medien akustische Kavitation auslösen und so lokalisierte Hotspots mit extremen Temperaturen und Drücken erzeugen, die genutzt werden können, um rational entworfene Metallkomplexe über unterschiedliche und sich ergänzende Mechanismen zu aktivieren. Dieser Übersichtsartikel bietet eine umfassende Analyse zweier primärer therapeutischer Modalitäten, die durch diesen Ansatz ermöglicht werden. In der sonodynamischen Therapie fungieren Metallzentren als Sonosensibilisatoren und erzeugen durch sonolumineszenz‐vermittelte Energieübertragung zytotoxische reaktive Sauerstoffspezies. Bei der ultraschallinduzierten Ligandenfreisetzung wird das mechanochemische Potenzial von Metallocenen und Koordinationspolymeren genutzt, wobei kavitationsinduzierte Scherkräfte die heterolytische Spaltung der Metall‐Liganden‐Bindung vorantreiben, um eine räumlich kontrollierte Freisetzung von bioaktiven Wirkstoffen und Katalysatoren zu erreichen. Ein entscheidender Vorteil dieser Plattform gegenüber lichtbasierten Therapieformen ist ihre Fähigkeit, tiefliegende Tumore zu erreichen. Durch die Zusammenführung aktueller Struktur‐Wirkungs‐Beziehungen und mechanistischer Erkenntnisse erstellt dieser Übersichtsartikel einen rationalen Leitfaden für die Entwicklung intelligenter Prodrugs auf Metallbasis der nächsten Generation und skizziert die entscheidenden Herausforderungen, darunter die Standardisierung akustischer Parameter, die Langzeittoxikologie von Metallfragmenten und die Genauigkeit translationaler Modellierung, die bewältigt werden müssen, um dieses aufstrebende Forschungsgebiet in Richtung klinischer Anwendung voranzubringen.